Technical Analysis for SCYX - SCYNEXIS, Inc.

Grade Last Price % Change Price Change
grade B 1.73 6.79% 0.11
SCYX closed up 6.79 percent on Tuesday, March 19, 2019, on 88 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical SCYX trend table...

Date Alert Name Type % Chg
Mar 19 Upper Bollinger Band Walk Strength 0.00%
Mar 19 Wide Bands Range Expansion 0.00%
Mar 19 Above Upper BB Strength 0.00%
Mar 19 Overbought Stochastic Strength 0.00%
Mar 19 Upper Bollinger Band Touch Strength 0.00%
Mar 18 Gilligan's Island Sell Setup Bearish Swing Setup 6.79%
Mar 18 Stochastic Reached Overbought Strength 6.79%
Mar 18 Upper Bollinger Band Walk Strength 6.79%
Mar 18 Wide Bands Range Expansion 6.79%
Mar 18 Above Upper BB Strength 6.79%

Older signals for SCYX ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
SCYNEXIS, Inc., a pharmaceutical company, is engaged in the discovery, development, and commercialization of anti-infectives to address unmet therapeutic needs. It is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug, which has completed Phase I clinical trials for the treatment of serious and life-threatening invasive fungal infections in humans against a range of Candida and Aspergillus fungal species, including drug resistant strains. The company, through its proprietary platform for cyclophilin inhibitors, is also developing clinical stage compounds, including SCY-635, an orally available cyclophilin inhibitor that has demonstrated clinical activity against Hepatitis C virus as a single agent and when dosed in combination with pegylated interferon and ribavirin; and SCY-641, a cyclophilin inhibitor with activity similar to cyclosporine, the active ingredient in Restasis and Optimmune drugs currently approved for dry eye disease in humans and dogs, respectively. In addition, it provides contract research and development services. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was founded in 1999 and is headquartered in Durham, North Carolina.
Medicine Medical Specialties Pharmaceutical Drugs Medication Anti Infectives Hepatitis C Interferon Pegylation
Is SCYX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 2.15
52 Week Low 0.35
Average Volume 1,435,604
200-Day Moving Average 1.2016
50-Day Moving Average 1.1098
20-Day Moving Average 1.3305
10-Day Moving Average 1.392
Average True Range 0.1216
ADX 36.14
+DI 43.6534
-DI 7.7312
Chandelier Exit (Long, 3 ATRs ) 1.4552
Chandelier Exit (Short, 3 ATRs ) 1.5248
Upper Bollinger Band 1.6309
Lower Bollinger Band 1.0301
Percent B (%b) 1.16
BandWidth 45.155956
MACD Line 0.1222
MACD Signal Line 0.0893
MACD Histogram 0.0329
Fundamentals Value
Market Cap 46.23 Million
Num Shares 26.7 Million
EPS -0.96
Price-to-Earnings (P/E) Ratio -1.80
Price-to-Sales 193.40
Price-to-Book 1.56
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.06
Resistance 3 (R3) 2.05 1.94 2.01
Resistance 2 (R2) 1.94 1.85 1.94 1.99
Resistance 1 (R1) 1.83 1.80 1.89 1.84 1.97
Pivot Point 1.72 1.72 1.74 1.72 1.72
Support 1 (S1) 1.61 1.63 1.67 1.62 1.49
Support 2 (S2) 1.50 1.58 1.50 1.47
Support 3 (S3) 1.39 1.50 1.46
Support 4 (S4) 1.40